Sutter Bay Medical Foundation

Merit Medical Systems received FDA premarket approval for its WRAPSODY Cell-Impermeable Endoprosthesis, designed to maintain long-term vessel patency for dialysis patients. The device, developed in 2010 with Dr. Bart Dolmatch, features a nitinol stent frame and multi-layered PTFE covering, aiming to improve outcomes for haemodialysis patients. Clinical trial results showed high primary patency rates at six months.

Merit Medical Systems announces FDA approval for WRAPSODY Cell-Impermeable Endoprosthesis, designed to extend vessel patency in dialysis patients. The device features a proprietary covering preventing tissue accumulation, enhancing radial force, and reducing stress on vessel walls. Clinical trial results show high patency rates, positioning WRAPSODY as a potential new standard of care. Merit plans to commercialize the device in the USA in 2025.

A study by Amer F. Alsoudi et al. suggests curcuma-based nutritional supplements (CBNS) may reduce the risk of age-related macular degeneration (AMD) and its progression. The study, involving 66,804 CBNS users and 1,809,440 non-users, found significantly lower risks of developing AMD and geographic atrophy, blindness, and needing anti-VEGF therapy among CBNS users. The authors recommend further studies to confirm these findings and explore safety and mechanisms.